Patents by Inventor Sarkis B. Kalindjian

Sarkis B. Kalindjian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bicyclo 2,2,2!octane derivatives
    Patent number: 5514683
    Abstract: The compounds of the formula I ##STR1## and their pharmaceutical acceptable salts, which are defined herein, are ligands for cholecystokinin and/or gastrin receptors.
    Type: Grant
    Filed: August 9, 1994
    Date of Patent: May 7, 1996
    Assignee: James Black Foundation Limited
    Inventors: Sarkis B. Kalindjian, Caroline M. R. Low, Iain M. McDonald, Robert A. D. Hull, Nigel P. Shankley, Ildiko M. Buck, Katherine I. M. Steel, Jonathan M. R. Davies, David J. Dunstone, Elaine A. Harper, Michael J. Pether, Michael J. Bodkin, Matthew J. Tozer, Martin L. Hudson
  • Tetrapeptide derivatives and analogues
    Patent number: 5486597
    Abstract: The C-terminal tetrapeptide of gastrin, Trp-Met-Asp-Phe-NH.sub.2, possesses gastrin pharmacological activity. Replacement of the methionyl moiety in the gastrin tetrapeptide, or its analogs, with a naphthylalanyl group produces compounds which interact with gastrin and/or cholecystokinin receptors, but have reduced gastrin and/or cholecystokinin agonist activity. Such partial agonists or antagonists of gastrin and/or cholecystokinin provide useful therapeutic agents.
    Type: Grant
    Filed: June 17, 1993
    Date of Patent: January 23, 1996
    Assignee: James Black Foundation Limited
    Inventors: Sarkis B. Kalindjian, Howard B. Broughton, Caroline M. R. Low, Iain M. McDonald, Robert A. D. Hull, Nigel P. Shankley, Ildiko M. Buck, Katherine I. M. Steel, Jonathan M. R. Davies
  • Derivatives of aspartic acid and glutamic acid having anticholecystokinin activity
    Patent number: 5399748
    Abstract: Arylsulfonamide derivatives of .alpha.-amino dicarboxylic acids such as aspartic acid and glutamic acid posses anti-cholecystokinin activity. They are useful in the treatment of cholecystokinin-related disorders such as anorexia nervosa, pancreatic inflammation, biliary tract disease, Zollinger-Ellison syndrome and various psychiatric disorders, as well as in the potentiation of opiate analgesia, and in the treatment of certain cancers.
    Type: Grant
    Filed: January 12, 1993
    Date of Patent: March 21, 1995
    Assignee: James Black Foundation Limited
    Inventors: Howard B. Broughton, Sarkis B. Kalindjian, Caroline M. R. Low, Iain M. McDonald, Robert A. D. Hull, Nigel P. Shankley
  • Hybrid proteins of human plasminogen and human t-PA, pharmaceutical compositions and methods of treatment
    Patent number: 5302390
    Abstract: A hybrid plasminogen activator which comprises the five kringle domains of plasminogen linked to the B-chain of t-PA or u-PA via an amino acid sequence comprising, respectively, the t-PA cleavage site between residues 275 and 276 and the cysteine residue 264 of t-PA or the u-PA cleavage site between residues 158 and 159 and the cysteine residue 148 of u-PA, or a derivative of a plasminogen activator comprising the serine protease domain of t-PA or u-PA, in which the catalytic site essential for plasminogen activator activity is blocked by a 2-aminobenzoyl group substituted in the 3- or 4-position with a halogen atom and optionally further substituted with one or more weakly electron-withdrawing or electon-donating groups, wherein the pseudo first order rate constant for hydrolysis of the derivative is in the range 6.0.times.10.sup.-5 to 4.0.times.10.sup.-4 sec.sup.-1 when measured in a buffer system consisting of 0.05M sodium phosphate, 0.1M sodium chloride, 0.
    Type: Grant
    Filed: September 29, 1992
    Date of Patent: April 12, 1994
    Assignee: Beecham Group plc
    Inventors: Michael J. Browne, Jeffery H. Robinson, Richard A. G. Smith, Sarkis B. Kalindjian